Fig. 4

Antitumor efficacy of CKD-602 in a CaSKi xenograft model. a. Schematic diagram of the treatment regimen of CKD-602. Groups of BALB/c-nude mice (five per group) were subcutaneously challenged with CaSki 4 × 106 CaSki tumor cells per mouse. b. Tumor volume in CaSki tumor-bearing mice in control mice and the CKD-602-treated mice. Results are expressed as mean ± SEM (*p < 0.05). c. Body weight of CaSki tumor-bearing mice in control mice and CKD-602-treated mice